Stomatology Health Care Center, Shenzhen Maternity and Child Healthcare Hospital Affiliated to Southern Medical University, Shenzhen 518048, China.
Biomed Res Int. 2020 Jun 15;2020:7589072. doi: 10.1155/2020/7589072. eCollection 2020.
To assess the efficacy of the autologous platelet concentrates (APCs) combined with autologous bone or bone substitute for the maxillary sinus floor lifting by a meta-analysis.
Electronic databases (PUBMED, Web of Science, EMBASE through OVID, and Cochrane Library) were searched until Dec 31, 2019, and only randomized controlled trials (RCTs) in English were identified. Outcome variables included histologic evaluation, the implant stability quotient values, and radiographic evaluation. Data were analyzed by Revman5.3; the estimate of effect sizes was expressed as the 95% confidence interval; and the risk of bias was evaluated using the Cochrane Collaboration tool.
11 RCTs involving 141 patients (214 sites) were included in our meta-analysis, which indicated that the differences in the percentage of contact length among newly formed bone (2.61%, 95% CI, -1.18% to 7.09%), soft tissue area (-0.15%, 95% CI, -0.54% to 0.24%), and residual bone substitute material (-5.10%, 95% CI, -10.56% to 0.36%) in the APC group lacked statistical significance. Besides, there was the same effect on the implant stability quotient (ISQ) values of APC group who underwent implant placement 4 months after sinus augmentation and control group who received implant placement 8 months after sinus augmentation (-0.48, 95% CI, -1.68 to 0.72). No significant effect of APCs on the bone density was found (1.05%, 95% CI, -1.69% to 3.82%).
The use of APCs in sinus augmentation may be further shorten the time required for bone graft maturation and allow earlier implant placement, but cannot enhance the bone formation in the long term. It is not currently recommended for routine use APCs as an osteoinductive material to bone grafting in sinus augmentation.
通过荟萃分析评估自体血小板浓缩物(APCs)联合自体骨或骨替代物用于上颌窦底提升的疗效。
检索电子数据库(PubMed、Web of Science、EMBASE 通过 OVID 和 Cochrane Library)至 2019 年 12 月 31 日,仅纳入英文的随机对照试验(RCT)。观察指标包括组织学评估、种植体稳定性指数(ISQ)值和影像学评估。采用 RevMan5.3 进行数据分析;效应大小的估计值表示为 95%置信区间;使用 Cochrane 协作工具评估偏倚风险。
纳入 11 项 RCT 共 141 例患者(214 个部位)。结果显示,在新骨形成的接触长度百分比、软组织面积和剩余骨替代材料方面,APCs 组与对照组之间差异无统计学意义[新骨形成的接触长度百分比分别为 2.61%(95%CI,-1.18%7.09%)、软组织面积分别为-0.15%(95%CI,-0.54%0.24%)和剩余骨替代材料分别为-5.10%(95%CI,-10.56%0.36%)]。另外,在接受上颌窦提升后 4 个月行种植体植入的 APC 组和接受上颌窦提升后 8 个月行种植体植入的对照组中,ISQ 值的变化也无显著差异[-0.48(95%CI,-1.680.72)]。也未发现 APCs 对骨密度有显著影响[1.05%(95%CI,-1.69%~3.82%)]。
在鼻窦提升术中使用 APCs 可能进一步缩短骨移植成熟所需的时间并允许更早地进行种植体植入,但不能长期增强骨形成。目前不建议将 APCs 常规用作诱导成骨材料用于鼻窦提升术的骨移植。